Research graph
References from Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2021 · External reference
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 · External reference
Epidemiology and risk factors of urothelial bladder cancer
10.1016/j.eururo.2012.07.033 · 2013 · External reference
Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes
10.1016/j.eururo.2015.08.037 · 2016 · External reference
Bladder Cancer: a review
10.1001/jama.2020.17598 · 2020 · External reference
Health-related quality of life after curative treatment for muscle-invasive bladder cancer
10.1038/s41585-022-00693-z · 2023 · External reference
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base
10.1016/j.eururo.2012.11.015 · 2013 · External reference
Current status of diagnosis and treatment of bladder cancer in China - analyses of Chinese Bladder Cancer Consortium database
10.1016/j.ajur.2015.04.016 · 2015 · External reference
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
10.1016/s1470-2045(23)00170-5 · 2023 · External reference
Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience
10.1016/j.eururo.2016.12.020 · 2017 · External reference
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
10.1056/nejmoa1106106 · 2012 · External reference
Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic
10.1200/jco.2016.69.2327 · 2017 · External reference
Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder
10.1016/j.eururo.2022.04.013 · 2022 · External reference
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
10.1038/s41591-020-1085-z · 2020 · External reference
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
10.1111/j.1464-410x.2009.09190.x · 2010 · External reference
A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer
2023 · External reference
Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma
10.1158/1078-0432.ccr-20-2488 · 2021 · External reference
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase ib/II dose-escalation and dose-expansion study
10.1016/j.annonc.2024.12.002 · 2025 · External reference
Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression
10.1200/jco.2024.42.16_suppl.4568 · 2024 · External reference
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial
10.1200/jco.2025.43.5_suppl.665 · 2025 · External reference
Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer
10.1056/nejmoa2408154 · 2024 · External reference
Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery
2020 · External reference
Antibody-drug conjugate-based therapeutics: state of the science
10.1093/jnci/djz035 · 2019 · External reference
Disitamab vedotin plus Toripalimab in HER2-expressing advanced urothelial cancer
10.1056/nejmoa2511648 · 2025 · External reference
Bladder Cancer: a review
10.1001/jama.2020.17598 · ExternalCitation · doi-reference
Current status of diagnosis and treatment of bladder cancer in China - analyses of Chinese Bladder Cancer Consortium database
10.1016/j.ajur.2015.04.016 · ExternalCitation · doi-reference
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase ib/II dose-escalation and dose-expansion study
10.1016/j.annonc.2024.12.002 · ExternalCitation · doi-reference
Epidemiology and risk factors of urothelial bladder cancer
10.1016/j.eururo.2012.07.033 · ExternalCitation · doi-reference
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base
10.1016/j.eururo.2012.11.015 · ExternalCitation · doi-reference
Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes
10.1016/j.eururo.2015.08.037 · ExternalCitation · doi-reference
Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience
10.1016/j.eururo.2016.12.020 · ExternalCitation · doi-reference
Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder
10.1016/j.eururo.2022.04.013 · ExternalCitation · doi-reference
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
10.1016/s1470-2045(23)00170-5 · ExternalCitation · doi-reference
Health-related quality of life after curative treatment for muscle-invasive bladder cancer
10.1038/s41585-022-00693-z · ExternalCitation · doi-reference
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
10.1038/s41591-020-1085-z · ExternalCitation · doi-reference
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
10.1056/nejmoa1106106 · ExternalCitation · doi-reference
Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer
10.1056/nejmoa2408154 · ExternalCitation · doi-reference
Disitamab vedotin plus Toripalimab in HER2-expressing advanced urothelial cancer
10.1056/nejmoa2511648 · ExternalCitation · doi-reference
Antibody-drug conjugate-based therapeutics: state of the science
10.1093/jnci/djz035 · ExternalCitation · doi-reference
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
10.1111/j.1464-410x.2009.09190.x · ExternalCitation · doi-reference
Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma
10.1158/1078-0432.ccr-20-2488 · ExternalCitation · doi-reference
Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic
10.1200/jco.2016.69.2327 · ExternalCitation · doi-reference
Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression
10.1200/jco.2024.42.16_suppl.4568 · ExternalCitation · doi-reference
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial
10.1200/jco.2025.43.5_suppl.665 · ExternalCitation · doi-reference
